ArticleImmunology2021
Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2
Article in Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Huaiqihuang Alleviates Imiquimod-Induced Psoriasis-Like Skin Lesions and Depressive-Like Behaviors in Mice.Current medical science · 2026Article
- The emerging role of T cells in depression.Frontiers in psychiatry · 2026Review
- Gut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and Toll-like receptor 4.BMC microbiology · 2025Article
- Article
- Disrupted betaine metabolism drives Th17 cell differentiation, mediating methamphetamine-induced depressive behaviors in male mice.Journal of neuroinflammation · 2025Article
- Review
- Inflammation-related biomarkers and berberine therapy in post-stroke depression: evidence from bioinformatics, machine learning, and experimental validation.Frontiers in neuroscience · 2025Article
- Depression and anxiety in multiple sclerosis. Review of a fatal combination.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV.The Journal of infectious diseases · 2024Article
- Antidepressant fluoxetine alleviates colitis by reshaping intestinal microenvironment.Cell communication and signaling : CCS · 2024Article
- Impact of the gut microbiota-Th17 cell axis on inflammatory depression.Frontiers in psychiatry · 2024Review
- Inflammation in the pathogenesis of depression: a disorder of neuroimmune origin.Neuronal signaling · 2023Review
- Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells.Pharmacological reviews · 2022Review
- Elevated proportion of TLR2- and TLR4-expressing Th17-like cells and activated memory B cells was associated with clinical activity of cerebral cavernous malformations.Journal of neuroinflammation · 2022Article
- Th17-cells in depression: Implication in multiple sclerosis.Frontiers in immunology · 2022Review
- Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice.Frontiers in immunology · 2022Review
- Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy.Frontiers in neurology · 2022Article
- Emerging Roles of T Helper Cells in Non-Infectious Neuroinflammation: Savior or Sinner.Frontiers in immunology · 2022Review
- Mechanistic Studies of Gypenosides in Microglial State Transition and its Implications in Depression-Like Behaviors: Role of TLR4/MyD88/NF-κB Signaling.Frontiers in pharmacology · 2022Article
- Role of Toll-Like Receptors in Neuroimmune Diseases: Therapeutic Targets and Problems.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated frequency of Th17-like cells expressing Toll-like receptors (TLRs) has been recently associated with relapsing-remitting multiple sclerosis (MS) pathogenesis, a chronic inflammatory demyelinating autoimmune disease of the central nervous system. We aimed to investigate the impact of current major depressive disorder (MDD) on the behaviour of these cells following in vitro stimulation with TLR2, TLR4, TLR5 and TLR9 agonists. Here, the level of both cell proliferation and cytokine production related to Th17/Tc17 phenotypes in response to TLR2 (Pam3C) and TLR4 (LPS) ligands was significantly higher in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.